Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Lamivudin, Tenofovirdisoproxil und Doravirin, ATC J05AR24

Conclusion of non-exclusive rebate contracts pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicines with the aforementioned active substance within the period from 01.06.2026 to 31.05.2028 with the possibility of concluding the contract at any time (open-house model). In the open house procedure, medicines according to the BfArM list pursuant to § 35 para. 5a SGB V (paediatric medicines) are excluded.